Effective February 14, 2017, BC Pharmacare has approved innohep for the additional indication of CAT for up to 6 months. For more information, please click here.
The following event report is the summary of Making Canada Better conference that was held this past November by Innovative Medicines Canada. Please click here to view the report.
Webinar Information: The upcoming federal budget may contain announcements related to the way healthcare is funded in Canada, including changes to the regulation of pharmaceutical prices. Value for taxpayer money...
The purpose of this survey is to provide us with the needed insights and perspectives about the use of Rituxan (Rituximab) for the treatment of patients with Philadelphia chromosome-negative, CD20 antigen positive, B-cell precursor...
Development of promising engineered T cell therapy part of $11 million investment in 16 collaborative research projects in novel therapies to cure cancer OTTAWA, ON – Wednesday, February 15, 2017, 10 a.m. ET - BioCanRx, and its partners, today...
Decisions on public reimbursement now in hands of provincial and territorial jurisdictions MONTREAL, Feb. 10, 2017 /CNW/ - Bristol-Myers Squibb Canada Co. today announced that the company has reached an...
OTTAWA, Feb. 8, 2017 /CNW/ - Researchers from The Ottawa Hospital Breast Health Centre and the Ottawa Integrative Cancer Centre (OICC) have opened the Ottawa site of the Lead-In to the Tomosynthesis Mammographic Imaging Screening...
FOR RELEASE Prostate Cancer Canada Network Ottawa (PCCNO) is pleased to announce that its 2017 conference “Prostate Cancer - Discover the Future” will be held at the Ottawa Convention and...
Last week, Prince Edward Island agreed to a new healthcare accord with the federal government, securing an additional $45.1 million over the next ten years. British Columbia, Alberta, Manitoba, Ontario...
On Friday, February 3rd, CCSN opened their doors in recognition of World Cancer Day! An annual event held at the CCSN office, this years’ edition was a huge success with...